Among the more problematic pathogens affecting cattle, Mycoplasma bovis (M. bovis) stands out for its involvement in chronic infections. The interaction between the outer makeup of the microorganism and the animal’s immune response contributes to its insidious nature, making treatment as well as prevention difficult.

Vaccine protocol discussions can be energetic and entertaining amongst calf raisers, consultants and veterinarians. It ultimately leads to comparing the current vaccine protocol to a large, well-established calf raiser in the region or even nationally. There can be value in this comparison, but the real value is understanding how these successful facilities arrived at their protocol.

A vet shares her experiences creating and implementing an autogenous vaccine for pinkeye, along with tips for treatment and prevention.

Described as a “cunning chameleon,” Mycoplasma bovis has vague symptoms with an insidious onset. It is difficult to diagnose, and treat, and producers may not even realize it is on their operation.

Mycoplasma bovis is a bacterium lacking a cell wall, which causes it to be resistant to beta-lactam antibiotics (penicillin, ampicillin, cephalosporins). Its unique metabolism also makes it resistant to sulpha drugs.

 Mycoplasma is not a new problem and has plagued dairy farms for over 50 years, so what are the factors that make this disease so dangerous and what have we learned about control and prevention?

One study done in 11 herds who had a history of BRD found M. bovis in 20% of the pre-weaned calves tested. It was the only bacteria associated with lung lesions seen on ultrasound, clinical scores of respiratory disease and lower average daily gains. 

Most producers know that calfhood pneumonia, or bovine respiratory disease (BRD), is one of the leading health concerns impacting calves on even the best-managed dairies. The disease challenges young calves face when they are most vulnerable can have lifelong productivity and profitability implications.